[Studying on the prevalence and mutation pattern of N348I which related to the resistance of HIV-1].
PMID: 22340881
2011
Zhonghua liu xing bing xue za zhi
Abstract: N348I always emerged, and combined with others mutations among patients of ART, whose frequencies were: 85.0% in combination with thymidine analog mutations (TAMs) and 52.5% with M184V/I, respectively.
Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
PMID: 19801944
2010
Journal of acquired immune deficiency syndromes (1999)
Abstract: RESULTS: The most common reverse transcriptase mutation was M184V/I (72%; n = 163); 11% of patients (n = 25) had only nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations and 17% (n = 38) had no known resistance mutations.
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Abstract: In women receiving dual or triple PLAT, respectively, postpartum M184V/I rates were 65% (95% by ASPCR) and 28.7% (51.6% by ASPCR), respectively (P < 0.01).
Result: Using population sequencing of plasma viruses, the M184V/I mutation was detected postpartum in 65.0% of women receiving dual PLAT throughout pregnancy compared to 28.7% of women treated with 3 drugs (p=0.004).
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Result: However, when analysed by CG, low-abundance viral species containing resistance mutations were detected in three of these four subjects at VF (L210W for Subject 8, Y188L for Subject 12 and M184I for Subject 13).
Result: The L210W and M184I mutations were treatment emergent for Subjects 8 and 13, respectively, while the NNRTI mutation Y188L that was observed by CG at VF for Subject 12 had also been detected at baseline by CG (but not by PG).
Table: M184I
Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.
PMID: 20038617
2010
Antimicrobial agents and chemotherapy
Abstract: Amdoxovir (AMDX) inhibits HIV-1 containing the M184V/I mutation and is rapidly absorbed and deaminated to its active metabolite, beta-D-dioxolane guanosine (DXG).
N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Conclusion: This finding is consistent with recent studies that show a strong association between N348I with TAMs, M184V/I and Y181C or that N348I is frequently observed in AZT- and/or ddI-containing therapies.
Introduction: N348I appears early in therapy and was found to be highly associated with TAMs, M184V/I and the NNRTI resistance mutations K103N, Y181C/I, and G190A/S.
HIV-1 proviral resistance mutations: usefulness in clinical practice.
Abstract: The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion.
Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
Introduction: DXG has shown good activity in vitro against HIV-1 strains resistant to lamivudine or emtricitabine (M184V/I) and strains containing zidovudine/stavudine-resistant thymidine analogue mutations (TAMs), including the 69SS double insert.
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
Abstract: M184V/I, K103N and V106A/M were the most common mutations.
Result: Among the 35 viremic patients failing a second-line regimen, 29% (n=10), 54% (n=19) and 6% (n=2) patients had mutations associated with NRTI resistance (mainly M184V/I, n=9), NNRTI resistance (mainly K103N, n=15), and major PI mutations respectively.
Result: Of the 94 viremic patients on the first-line regimen, 64% (n=60), 81% (n=76), and 2% (n=2) had evidence of NRTI, NNRTI, and PI resistance respectively; M184V/I and K103N<
HIV mutation literature information.
PMID: 
2011
Zhonghua liu xing bing xue za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT